Verona Pharma
plc
("Verona Pharma" or the
"Company")
Notice of
Results
10 August 2016, Cardiff –
Verona Pharma plc (AIM: VRP), the drug development company focused
on first-in-class medicines to treat respiratory diseases, expects
to announce its interim results for the six months ended
30 June 2016 on Tuesday 13 September 2016.
-Ends-
For further information please
contact:
| Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
| N+1 Singer |
Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer |
|
|
|
| FTI Consulting |
Tel: +44 (0)20 3727 1000 |
| Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biotech company
focused on the development of innovative prescription medicines to
treat respiratory diseases with significant unmet medical needs,
such as chronic obstructive pulmonary disease (COPD), asthma and
cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in phase II trials as a nebulised maintenance treatment
for COPD patients with moderate to severe disease and possibly as a
treatment of acute exacerbations of COPD in the hospital setting.
The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and
therefore has both bronchodilator and anti-inflammatory effects,
which are essential to the improvement of patients with COPD and
asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD and
asthma maintenance therapy. The Company is also exploring the
potential of the drug in different diseases, such as cystic
fibrosis, where it is in pre-clinical testing and has recently
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.